Increment 发表于 2025-3-26 21:21:17

http://reply.papertrans.cn/1/84/8346/8346-31.png

Ingenuity 发表于 2025-3-27 04:32:05

http://reply.papertrans.cn/1/84/8346/8346-32.png

宣传 发表于 2025-3-27 06:10:52

http://reply.papertrans.cn/1/84/8346/8346-33.png

superfluous 发表于 2025-3-27 10:24:08

Submitted on: 10 November 2006.
Revised on: 07 January 2007.
Accepted on: 05 March 2007.

___________________Endocrine Metabolic & Immune Disorders-Drug Targets

分离 发表于 2025-3-27 15:19:11

http://reply.papertrans.cn/1/84/8346/8346-35.png

exigent 发表于 2025-3-27 20:38:20

http://reply.papertrans.cn/1/84/8346/8346-36.png
页: 1 2 3 [4]
查看完整版本: SCIE期刊Endocrine Metabolic & Immune Disorders-Drug Targets 2024/2025影响因子:2.108 (ENDOCR METAB IMMUNE) (1871-5303). (ENDOC